Literature DB >> 2545784

Different membrane anchors of Fc gamma RIII (CD16) on K/NK-lymphocytes and neutrophils. Protein- vs lipid-anchor.

E Ueda1, T Kinoshita, J Nojima, K Inoue, T Kitani.   

Abstract

Fc gamma RIII (CD16), the type three receptor for the Fc portion of IgG, is expressed on neutrophils, killer (K)/NK lymphocytes and macrophages. K/NK lymphocyte Fc gamma RIII, which plays a role in antibody-dependent cellular cytotoxicity, is an efficient signal transducing molecule, whereas neutrophil Fc gamma RIII, which plays a role in immune-complex clearance, seems less efficient in signal transduction. Neutrophil Fc gamma RIII has been reported to be a glycan-phosphatidylinositol-anchored membrane protein. Our studies suggest that K/NK lymphocyte Fc gamma RIII is protein-anchored rather than glycan-phosphatidylinositol-anchored. That is, K/NK lymphocyte Fc gamma RIII was resistant to phosphatidylinositol-specific phospholipase C and surface expression of Fc gamma RIII was not affected on K/NK lymphocytes from patients with paroxysmal nocturnal hemoglobinuria, a disorder of hemopoietic stem cells resulting in deficient expression of glycan-phosphatidylinositol-anchored proteins. Different membrane anchoring mechanisms of the Fc gamma RIII may account for different consequences of the ligand binding to two cell types.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545784

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Characterization and expression of an Fc gamma receptor cDNA cloned from rat natural killer cells.

Authors:  D L Zeger; P M Hogarth; D W Sears
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 2.  Fc receptor-mediated signal transduction.

Authors:  C T Lin; Z Shen; P Boros; J C Unkeless
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

3.  An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus.

Authors:  M R Clark; L Liu; S B Clarkson; P A Ory; I M Goldstein
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  Preferential expression of human Fc gamma RIIIPMN (CD16) in paroxysmal nocturnal hemoglobinuria. Discordant expression of glycosyl phosphatidylinositol-linked proteins.

Authors:  J C Edberg; J E Salmon; M Whitlow; R P Kimberly
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

5.  Identification of high-affinity anti-CD16A allotype-independent human antibody domains.

Authors:  Wei Li; Hongjia Yang; Dimiter S Dimitrov
Journal:  Exp Mol Pathol       Date:  2016-10-03       Impact factor: 3.362

6.  Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

Authors:  W D Ratnoff; J J Knez; G M Prince; H Okada; P J Lachmann; M E Medof
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 7.  Functional regulation of human neutrophil Fc gamma receptors.

Authors:  Periasamy Selvaraj; Nimita Fifadara; Shanmugam Nagarajan; Ashley Cimino; Guixian Wang
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor.

Authors:  Raoul A Droeser; Christian Hirt; Serenella Eppenberger-Castori; Inti Zlobec; Carsten T Viehl; Daniel M Frey; Christian A Nebiker; Raffaele Rosso; Markus Zuber; Francesca Amicarella; Giandomenica Iezzi; Giuseppe Sconocchia; Michael Heberer; Alessandro Lugli; Luigi Tornillo; Daniel Oertli; Luigi Terracciano; Giulio C Spagnoli
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

9.  Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  M Takahashi; J Takeda; S Hirose; R Hyman; N Inoue; T Miyata; E Ueda; T Kitani; M E Medof; T Kinoshita
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.